No Data
No Data
Meinong Biology (301156.SZ): Shareholder Li Da has cumulatively reduced 0.3412 million shares of the company's stock.
On August 14th, Gelonews reported that Meino Bio (301156.SZ) announced that a specific shareholder, Lida Stock, has reached the deadline for their shareholding reduction plan, and has reduced their shares in the company by 0.3412 million shares.
MinoBio (301156.SZ): The main products include functional fodder additives, nutritional fodder additives and enzymatic protein fodder raw materials.
On August 12th, Gelonhui reported that Meino Bio (301156.SZ) stated on their investor platform that the company's main products include functional fodder additives, nutritional fodder additives, and enzymatic protein fodder materials. Vitamins are part of the raw materials for one of the company's nutritional fodder additives, 'rumen vitamins'.
Meinong Biotechnology (301156.SZ): Cumulative repurchased 0.94% of shares.
On August 1st, GeLongHui reported that as of July 31st, 2024, the company has repurchased a total of 1,361,865 shares through a stock repurchase dedicated securities account using the centralized bidding trading method, accounting for 0.94% of the company's current share capital. The highest fill price was 16.69 yuan/share, the lowest fill price was 14.26 yuan/share, and the total transaction amount was 21,290,339.5 yuan (excluding transaction fees). This share repurchase is in compliance with the company's established share repurchase plan and relevant laws and regulations.
Shanghai Menon Animal Nutrition Technology Co., Ltd.'s (SZSE:301156) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Meinong Biology (301156.SZ): Specializing in R&D, production and sales of feed additives and enzymolysis protein feed ingredients
Gelonghui, May 21丨Meinong Biotech (301156.SZ) said on the investor interactive platform that the company specializes in R&D, production and sales of feed additives and enzymolysis protein feed ingredients. The company always adheres to the business philosophy of “technology drives value, innovation drives development”, implements the customer value proposition of “product leadership, value service, partner growth”, and implements a “centralized differentiation” development strategy. At the product level, adhere to the product strategy of “classification and full nutrition”; at the market level, adhere to the market strategy of “deeply cultivating the domestic market and expanding overseas markets”, and continuously enhance the company's core competition with multiple strategies
Meinong Biotech (301156.SZ): It has now established a sales network in Brazil and other countries and regions
Gelonghui, May 14, 丨 Meinong Biotech (301156.SZ) recently said during a survey reception from institutional investors that the company has always been committed to exploring and developing the international market, and has laid a good foundation for the international market for more than 20 years. At present, the company has established sales networks in various countries and regions such as Vietnam, Russia, Thailand, Myanmar, the Philippines, Japan, South Korea, Pakistan, Bangladesh, Egypt, Jordan, Turkey, and Brazil. The company's future development plan for overseas business: (1) Following the country's “Belt and Road” policy, the company will focus on developing the Southeast Asian market, South Asia and the Middle East market. (2) At
No Data